Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

[1]  A. Gajjar,et al.  Neurologic impairments from pediatric low‐grade glioma by tumor location and timing of diagnosis , 2018, Pediatric blood & cancer.

[2]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[3]  S. Pfister,et al.  Pediatric low-grade gliomas: next biologically driven steps , 2018, Neuro-oncology.

[4]  M. Prados,et al.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.

[5]  K. Ligon,et al.  Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[7]  D. Johnston,et al.  Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Ligon,et al.  Pediatric low-grade gliomas: implications of the biologic era , 2016, Neuro-oncology.

[9]  O. Witt,et al.  Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study , 2016, PloS one.

[10]  I. Pollack,et al.  Nonrandomized comparison of neurofibromatosis type 1 and non–neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low‐grade glioma: A report from the Children's Oncology Group , 2016, Cancer.

[11]  Stefan M. Pfister,et al.  Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets , 2016, Acta Neuropathologica.

[12]  V. Ramaswamy,et al.  Low Grade Gliomas in Children , 2016, Journal of child neurology.

[13]  David T. W. Jones,et al.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. , 2014, Neuro-oncology.

[14]  R. McLendon,et al.  Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. , 2014, Neuro-oncology.

[15]  R. Beroukhim,et al.  Long-Term Outcome of 4,040 Children Diagnosed With Pediatric Low-Grade Gliomas: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database , 2014, Pediatric blood & cancer.

[16]  B. Korf,et al.  Recommendations for imaging tumor response in neurofibromatosis clinical trials , 2013, Neurology.

[17]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[18]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[19]  T. Merchant,et al.  Longitudinal investigation of adaptive functioning following conformal irradiation for pediatric craniopharyngioma and low-grade glioma. , 2013, International journal of radiation oncology, biology, physics.

[20]  Gilbert Vezina,et al.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Uri Tabori,et al.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. , 2012, Neuro-oncology.

[22]  C. Hawkins,et al.  Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Grever,et al.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Peter J Houghton,et al.  Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.

[25]  M. Fisher,et al.  Pediatric Low-Grade Gliomas , 2009, Journal of child neurology.

[26]  L. Goumnerova,et al.  Medical, psychological, cognitive and educational late‐effects in pediatric low‐grade glioma survivors treated with surgery only , 2009, Pediatric blood & cancer.

[27]  D. Hargrave.  Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy , 2009, British Journal of Neurosurgery.

[28]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[29]  D. Evans,et al.  Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Paquier,et al.  Functional outcome after low‐grade astrocytoma treatment in childhood , 2006, Cancer.

[31]  S. Schulz,et al.  Radiotherapy in the treatment of low-grade astrocytomas , 1995, Child's Nervous System.

[32]  V. Blair,et al.  Radiotherapy in the treatment of low-grade astrocytomas , 1995, Child's Nervous System.

[33]  J. Friedman,et al.  Clinical and genetic aspects of neurofibromatosis 1 , 2010, Genetics in Medicine.